In a new report, adolescents with genotype 2 or 3 HCV infection who were given sofosbuvir and ribavirin showed a near 100% sustained virologic response. This study is the beginning of a new wave of treatments for paediatric HCV infection, forming part of a global strategy to eradicate viral hepatitis.
Refers to Wirth, S. et al. Sofosbuvir and ribavirin in adolescents 12 to 17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatologyhttp://dx.doi.org/10.1002/hep.29278 (2017)